Tag: Create

In mid-January, Pfizer (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) gave the nod to Cibinqo as a treatment for patients with moderate to severe atopic dermatitis (eczema) whose disease wasn’t adequately controlled with other treatments. Why did the FDA approve Cibinqo for moderate to severe eczema patients? And what could this mean […]